Compare · LAB vs WAT
LAB vs WAT
Side-by-side comparison of Standard BioTools Inc. (LAB) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LAB and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 159.6x LAB ($255.2M).
- Over the past year, LAB is down 49.6% and WAT is up 39.6% - WAT leads by 89.2 points.
- LAB has been more active in the news (9 items in the past 4 weeks vs 6 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 5 for LAB).
- Company
- Standard BioTools Inc.
- Waters Corporation
- Price
- $0.65-0.08%
- $414.21+0.88%
- Market cap
- $255.2M
- $40.72B
- 1M return
- -15.85%
- +11.60%
- 1Y return
- -49.61%
- +39.61%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- 1995
- News (4w)
- 9
- 6
- Recent ratings
- 5
- 25
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest LAB
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,480,823 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 28,195 shares, decreasing direct ownership by 1% to 2,534,859 units (SEC Form 4) (for withholding tax)
- President & CEO Egholm Michael covered exercise/tax liability with 97,627 shares, decreasing direct ownership by 2% to 6,137,704 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form 10-Q filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools Reports Second Quarter 2026 Financial Results
- President & CEO Egholm Michael covered exercise/tax liability with 362,625 shares, decreasing direct ownership by 5% to 6,235,331 units (SEC Form 4) (tax withholding)
- SEC Form 425 filed by Standard BioTools Inc.
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)